Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?
- 29 April 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 91 (9), 1371-1381
- https://doi.org/10.1007/s00277-012-1458-6
Abstract
The objective of this study was to investigate the health-related quality of life (HRQOL) aspects valued the most by patients with chronic myeloid leukemia (CML) receiving targeted therapies (TT), and to compare their perception with that of health-care professionals’ (HCPs). Semi-structured interviews were conducted with 137 CML patients receiving TT from five different countries. An additional sample of 99 CML patients, completing an online interview, was considered for supportive analyses. A sample of 59 HCPs from 12 countries also participated in the study. Patients and HCPs were asked to rate and rank the importance of a predefined list of 74 HRQOL aspects of potential relevance for CML patients. Patients and HCPs agreed that the following five aspects are most important: fatigue, muscle cramps, swelling, worries, and uncertainty about health condition in the future, and importance of social support in coping with the disease. However, the difference in rankings between the two groups was substantial with respect to other HRQOL aspects investigated. Patients valued some issues related to symptoms much higher than HCPs, thus suggesting that a better symptom management could be the crucial aspects to improve HRQOL of CML patients.Keywords
This publication has 19 references indexed in Scilit:
- Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomesCritical Reviews in Oncology/Hematology, 2012
- Educational Session: Managing Chronic Myeloid Leukemia as a Chronic DiseaseHematology-American Society Hematology Education Program, 2011
- Use of Patient-Reported Outcomes to Improve the Predictive Accuracy of Clinician-Reported Adverse EventsJNCI Journal of the National Cancer Institute, 2011
- Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general populationBlood, 2011
- Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsBlood, 2011
- Clinical Cancer Advances 2010: Annual Report on Progress Against Cancer From the American Society of Clinical OncologyJournal of Clinical Oncology, 2010
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2010
- Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Health care providers underestimate symptom intensities of cancer patients: A multicenter European studyHealth and Quality of Life Outcomes, 2010
- Patients’ and health care professionals’ evaluation of health-related quality of life issues in bone metastasesEuropean Journal Of Cancer, 2009